Mucin B5 rs (35705950) Gene Polymorphism in Interstitial Lung DiseasesNCT06498141
MucinB5 Gene Polymorphism and Leucocytes Telomere Length in Interstitial Lung Diseases
An observational study of Mucin B5 rs (35705950) Gene Polymorphism in Interstitial Lung Diseases, run by Sohag University at 1 site in Egypt.
Trial summary
This is an observertional study aimed at Study the association between Mucin B5 rs (35705950) gene polymorphism and Leucocytes telomere length in relation to interstitial lung diseases. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Mucin B5 rs (35705950) Gene Polymorphism in Interstitial Lung Diseases
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Oct 2023to 31 Dec 2024
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: patients with interstitial lung diseases in our center in sohag university hospital
Who may be able to join
- This study will include patients with interstitial lung diseases aged above 18 years old.
Who cannot join
- patients with emphysema or obstructive lung diseases.
- patients with active cancer
- End stage renal failure (GFR < 30 ml/min) or on dialysis
- Liver cell failure
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Sohag university hosoital
Sohag
Amera Morad Foad Hamdy, Professor, +201006591449, ameramoradfoad@gmail.com
About this study
Official title: MucinB5 rs (35705950) Gene Polymorphism and Leucocytes Telomere Length in Relation to Interstitial Lung Diseases.
This is an observertional study aimed at Study the association between Mucin B5 rs (35705950) gene polymorphism and Leucocytes telomere length in relation to interstitial lung diseases.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Diseased | patients with interstitial lung diseases fulfilling the inclusion criteria. | |
| Control | Healthy subjects |
What is being measured
The primary outcome is the main question the study is designed to answer.
MucinB5 rs (35705950) gene polymorphism
whether homogenetic or heterogenetic
Measured: 6 Months
Leucocytes telomere length
Measurement of the relative length of WBCs telomere in patints with interstitial pulmonary fibrosis
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2024
- Study start1 Oct 2023
- Primary completion1 Oct 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mucin B5 rs (35705950) Gene Polymorphism in Interstitial Lung DiseasesStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amera Morad Foad, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06498141
- Sponsor's protocol ID
- Soh-Med-23-02-21
- Status last verified
- Jul 2024
- First submitted
- 6 Jul 2024
- Last updated
- 12 Jul 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MucinB5 rs (35705950) Gene Polymorphism and Leucocytes Telomere Length in Relation to Interstitial Lung Diseases.
- ClinicalTrials.gov ID
- NCT06498141
- Acronym / sponsor ID
- Soh-Med-23-02-21
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 1 Oct 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 12 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observertional study aimed at Study the association between Mucin B5 rs (35705950) gene polymorphism and Leucocytes telomere length in relation to interstitial lung diseases.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 6 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Diseased | – | –patients with interstitial lung diseases fulfilling the inclusion criteria. |
| Control | – | –Healthy subjects |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- patients with interstitial lung diseases in our center in sohag university hospital
Key inclusion criteria (1 listed)
- This study will include patients with interstitial lung diseases aged above 18 years old.
Key exclusion criteria (4 listed)
- patients with emphysema or obstructive lung diseases.
- patients with active cancer
- End stage renal failure (GFR < 30 ml/min) or on dialysis
- Liver cell failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
MucinB5 rs (35705950) gene polymorphism
Time frame: 6 Months
whether homogenetic or heterogenetic
Leucocytes telomere length
Time frame: 6 months
Measurement of the relative length of WBCs telomere in patints with interstitial pulmonary fibrosis
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jul 2024.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mucin B5 rs (35705950) Gene Polymorphism in Interstitial Lung Diseases, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Amera Morad Foad, professor (+201006591449, ameramoradfoad@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MucinB5 rs (35705950) gene polymorphism (time frame: 6 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2024; AzTrials last refreshed its copy on 6 Nov 2026.